Positive Clinical Trial Results, Regulatory Wins, and New Appointments - Research Report on Incyte, Edwards, ACADIA

   Positive Clinical Trial Results, Regulatory Wins, and New Appointments -
   Research Report on Incyte, Edwards, ACADIA Pharmaceuticals, Alnylam, and
                                   Ironwood

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, August 26, 2013

NEW YORK, August 26, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Incyte
Corporation (NASDAQ: INCY), Edwards Lifesciences Corp. (NYSE: EW), ACADIA
Pharmaceuticals Inc. (NASDAQ: ACAD), Alnylam Pharmaceuticals Inc. (NASDAQ:
ALNY), and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Incyte Corporation Research Report

On August 21, 2013, Incyte Corporation (Incyte) announced top-line results of
the Phase II, randomized, double-blind, placebo-controlled RECAP trial of
ruxolitinib, the Company's oral JAK1 and JAK2 inhibitor, in combination with
capecitabine in patients with recurrent or treatment refractory metastatic
pancreatic cancer. The Company stated that the hazard ratio (HR) for overall
survival (OS) in the intent to treat population was 0.79 (one-sided p=0.12),
and in a pre-specified subgroup analysis conducted in patients identified
prospectively as most likely to benefit from JAK pathway inhibition, the HR
for OS was 0.47 (one-sided p=0.005). In addition, Incyte reported that within
the pre-specified subgroup of patients, which represented 50% of the
randomized population, 6 month survival in the ruxolitinib arm was 42% vs. 11%
for placebo. Paul A. Friedman, M.D., Incyte's President and CEO said, "Coupled
with the overall survival benefit observed in the ongoing Phase III trials in
myelofibrosis, these results solidify our belief in the therapeutic
opportunity that exists for Jakafi, and provide us with an acceleration
strategy to advance our JAK1 inhibitor portfolio into additional areas of
unmet medical need." The Full Research Report on Incyte Corporation -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-21/INCY]

--

Edwards Lifesciences Corp. Research Report

On August 21, 2013, Edwards Lifesciences Corp. (Edwards) announced that
Japan's Central Social Insurance Medical Council (Chuikyo) has given consent
to the recommendation by the Japanese Ministry of Health, Labor, and Welfare's
(MHLW) expert review panel to provide reimbursement for the Edwards SAPIEN XT
transcatheter aortic heart valve. According to the Company, with this approval
Chuikyo established a reimbursement of 4.5 million yen (c.$46,000) for when
the SAPIEN XT valve is used in the treatment of patients with severe
symptomatic aortic stenosis. The Company informed that the reimbursement is
scheduled to go into effect on October 1, 2013. The Full Research Report on
Edwards Lifesciences Corp. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-21/EW]

--

ACADIA Pharmaceuticals Inc. Research Report

On August 19, 2013, ACADIA Pharmaceuticals Inc. (ACADIA) announced the
appointment of Terrence Moore as the Company's Executive Vice President and
Chief Commercial Officer, with immediate effective. According to the Company,
prior to joining ACADIA, Mr. Moore served as a principal of Cook-Moore
Consulting and also served as Vice President at Transcept Pharmaceuticals
where he was responsible for commercial strategy, business development, and
commercial alliance activities. The Company also stated that in his new role,
Mr. Moore will be responsible to lead ACADIA's commercial activities. Uli
Hacksell, Ph.D, CEO of ACADIA Pharmaceuticals, said, "Terry's marketing
expertise and demonstrated ability to execute will help position ACADIA for
success in the planned launch of pimavanserin in Parkinson's disease psychosis
and for effective life cycle management in order to maximize pimavanserin's
commercial potential." The Full Research Report on ACADIA Pharmaceuticals Inc.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-21/ACAD]

--

Alnylam Pharmaceuticals Inc. Research Report

On August 20, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that the
U.S. Food and Drug Administration (FDA) has granted an Orphan Drug Designation
(ODD) to ALN-AT3 as a therapeutic for the treatment of hemophilia A. Earlier,
on August 14, 2013, the Company announced that the FDA granted ODD to ALN-AT3
for the treatment of hemophilia B. Saraswathy Nochur, Ph.D., Senior Vice
President, Regulatory Affairs and Quality Assurance at Alnylam, said, "We are
very pleased that the FDA has granted Orphan Drug Designation for ALN-AT3 now
for both the treatment of hemophilia A and hemophilia B. As a subcutaneously
delivered RNAi therapeutic, we believe it represents an innovative approach
for the management of hemophilia and has great potential to make a meaningful
impact in the treatment of this often debilitating bleeding disorder." The
Company also intends to file an investigational new drug (IND) application for
ALN-AT3 in Q4 2013 and initiate a Phase I clinical trial in early 2014. The
Full Research Report on Alnylam Pharmaceuticals Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.investorsreports.com/report/2013-08-21/ALNY]

--

Ironwood Pharmaceuticals, Inc. Research Report

On August 21, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood) announced the
appointment of Michael Hall, MB. BCH as the Company's Senior Vice President
of Clinical Development. According to Ironwood, Dr. Hall will lead its
clinical research, clinical development, clinical operations, biostatistics,
and pharmacovigilance teams. In addition, Ironwood stated that Mr. Hall will
oversee clinical trials investigating additional appropriate populations for
linaclotide, as well as the Company's pipeline of early development
candidates. Prior to joining Ironwood, Dr. Hall served as chief medical
officer and senior vice president at Repligen Corp. Mark Currie, Ph.d., Senior
Vice President, Chief Scientific Officer, and President of Research and
Development at Ironwood, said, "Michael's unique combination of drug
development experience, deep scientific knowledge, patient-oriented medical
perspective, and proven leadership capabilities will be of significant value
in supporting our clinical development activities." The Full Research Report
on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-08-21/IRWD]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Investors' Reports

Contact: Kristi Saunders CONTACT PHONE: +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.